



## PERSONAL INFORMATION

**Prof. Luca Bertero**

 Pathology Unit, Dept. Medical Sciences  
University of Turin  
Via Santena 7  
10126 Torino  
Italy

 +39 011/6336181

 luca.bertero@unito.it

## CURRENT EMPLOYMENT

- December 2022-Today **Associate professor of Pathology**  
Department of Medical Sciences, University of Turin, Turin, Italy
- December 2019-Today **Consultant pathologist**  
"Città della Salute e della Scienza di Torino" University Hospital, Turin, Italy

PREVIOUS WORK  
EXPERIENCES AND  
QUALIFICATIONS

- March 2021 **Italian national scientific license – Role: Associate professor – Academic discipline: Anatomic pathology (expiration date: 29/03/2031)**
- December 2019-December 2022 **Tenure track researcher (Academic discipline: MED/08 – Anatomic pathology)**  
Pathology Unit, Department of Medical Sciences, University of Turin, Italy
- February 2012-Today **Registration with the Province of Turin Medical Association**  
Registration number: 22285. Registration date: 27/02/2012.  
Turin, Italy

## EDUCATION AND TRAINING

- October 2017-January 2020 **PhD in Biomedical Sciences and Oncology (XXXIII Cycle), University of Turin**  
PhD thesis: "Evaluation of DNA methylation profiles for malignant pleural mesothelioma diagnosis"  
(PhD program director: Prof. Emilio Hirsch, Supervisor: Prof. Paola Cassoni)  
Turin, Italy
- April 2018-October 2018 **Visiting physician - Neuropathology Department/German Cancer Research Center, University of Heidelberg**  
Director: Prof. Andreas von Deimling  
Heidelberg, Germany
- December 2014-December 2018 **Anatomic Pathology residency – University of Turin**  
Final mark: 70/70 cum laude  
Thesis: Atypical and anaplastic meningiomas: creation and validation of a histopathological

- prognostic score (School director: Prof. Achille Pich, Thesis supervisor: Prof. Paola Cassoni).  
Turin, Italy
- November 2013-July 2014 **Research trainee - Project “Evaluation of efficacy of chemotherapy as upfront treatment for gliomatosis cerebri” – Neuro-oncology Division, Department of Neurosciences, University of Turin**  
Supervisor: Prof. Riccardo Soffietti  
Turin, Italy
- March 2013 **Observership – Neuro-Oncology Department, The University of Texas – MD Anderson Cancer Center**  
Supervisor: Dr. John De Groot  
Houston, Texas, USA
- November 2012-July 2013 **Research trainee - Project “New diagnostic and therapeutic modalities in low grade gliomas treatment” – Neuro-oncology Division, Department of Neurosciences, University of Turin**  
Supervisor: Prof. Riccardo Soffietti  
Turin, Italy
- 2012 **Italian national licensure examination to practice medicine, University of Turin**  
2011 second session  
Turin, Italy
- 2005-2011 **Medicine and Surgery degree – University of Turin**  
Final mark: 110/110 cum laude  
Thesis: “Multicentric, prospective phase II study of dose-dense chemotherapy in low grade oligodendroglial tumors: response and molecular factors of predictive value”. (Thesis supervisor: Prof. Riccardo Soffietti)  
Turin, Italy
- 2010 **Summer School on Clinical Neurology and Neurosurgery, University of Groningen**  
Groningen, Netherlands

## SCIENTIFIC ACTIVITY

Overall research profile (updated on 21/03/2023)

Total indexed publications (PubMed): 110

Total citations (Scopus): 1331

h-index (Scopus): 18

## Articles (indexed in PubMed)

1. Borella F, Marozio L, Bertschy G, Botta G, **Bertero L**, Cassoni P, Maina A, Cosma S, Benedetto C. Placenta-mediated pregnancy complications in women with a history of late fetal loss and placental infarction without thrombophilia: risk of recurrence and efficacy of pharmacological prophylactic interventions. A 10-year retrospective study. *J Matern Fetal Neonatal Med*. 2023 Dec;36(1):2183748. doi: 10.1080/14767058.2023.2183748.
2. Borella F, Mitidieri M, Cosma S, Benedetto C, **Bertero L**, Fucina S, Ray-Coquard I, Carapezzi A, Ferraioli D. Update on Prognostic and Predictive Markers in Mucinous Ovarian Cancer. *Cancers (Basel)*. 2023 Feb 12;15(4):1172. doi: 10.3390/cancers15041172.
3. Vallero SG, **Bertero L**, Morana G, Sciortino P, Bertin D, Mussano A, Ricci FS, Peretta P, Fagioli F. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type. *Front Oncol*. 2023 Jan 16;12:1082062. doi: 10.3389/fonc.2022.1082062. eCollection 2022.
4. Gambella A, **Bertero L**, Rondón-Lagos M, Verdun Di Cantogno L, Rangel N, Pitino C, Ricci AA, Mangherini L, Castellano I, Cassoni P. FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations. *Int J Mol Sci*. 2023 Jan 10;24(2):1342. doi: 10.3390/ijms24021342.
5. Berton AM, Prencipe N, **Bertero L**, Baldi M, Bima C, Corsico M, Bianchi A, Mantovani G, Ferraù F, Sartorato P, Gagliardi I, Ghigo E, Grottoli S. Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study. *J Clin Med*. 2022 Dec 20;12(1):25. doi: 10.3390/jcm12010025.
6. **Bertero L**, Ricci AA, Tampieri C, Cassoni P, Modena P. Ependymomas. *Pathologica*. 2022 Dec;114(6):436-446. doi: 10.32074/1591-951X-817.
7. Rudà R, Bruno F, Pellerino A, Pronello E, Palmiero R, **Bertero L**, Crasto S, Polo V, Vitaliani R, Trincia E, Internò V, Porta C, Soffietti R. Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy? *J Neurooncol*. 2022 Nov;160(2):389-402. doi: 10.1007/s11060-022-04155-9.
8. Metovic J, Borella F, D'Alonzo M, Biglia N, Mangherini L, Tampieri C, **Bertero L**, Cassoni P, Castellano I. FOXA1 in Breast Cancer: A Luminal Marker with Promising Prognostic and Predictive Impact. *Cancers (Basel)*. 2022 Sep 27;14(19):4699. doi: 10.3390/cancers14194699.
9. Gambella A, Pitino C, Barreca A, Nocifora A, Giarin MM, **Bertero L**, Biancone L, Roccatello D, Papotti M, Cassoni P. DNAJB9 Is a Reliable Immunohistochemical Marker of Fibrillary Glomerulonephritis: Evaluation of Diagnostic Efficacy in a Large Series of Kidney Biopsies. *Biomedicines*. 2022 Aug 27;10(9):2102. doi: 10.3390/biomedicines10092102.
10. Metovic J, Napoli F, Osella-Abate S, **Bertero L**, Tampieri C, Orlando G, Bianchi M, Carli D, Fagioli F, Volante M, Papotti M. Overexpression of INSM1, NOTCH1, NEUROD1, and YAP1 genes is associated with adverse clinical outcome in pediatric neuroblastoma. *Virchows Arch*. 2022 Dec;481(6):925-933. doi: 10.1007/s00428-022-03406-4.
11. Borella F, Cosma S, Ferraioli D, Ray-Coquard I, Chopin N, Meeus P, Cockenpot V, Valabrega G, Scotto G, Turinetto M, Biglia N, Fuso L, Mariani L, Franchi D, Urbinati AMV, Pino I, Bertschy G, Preti M, Benedetto C, Castellano I, Cassoni P, **Bertero L**. ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A

- Multicenter Retrospective Cohort Study of Tertiary Centers. **Ann Surg Oncol**. 2022 Dec;29(13):8317-8318. doi: 10.1245/s10434-022-12479-z.
12. Saaid A, Monticelli M, Ricci AA, Orlando G, Botta C, Zeppa P, Bianconi A, Osella-Abate S, Bruno F, Pellerino A, Rudà R, Cassoni P, Garbossa D, Cofano F, **Bertero L**. Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma. **Genes (Basel)**. 2022 Aug 12;13(8):1439. doi: 10.3390/genes13081439.
  13. Borella F, Cosma S, Ferraioli D, Ray-Coquard I, Chopin N, Meeus P, Cockenpot V, Valabrega G, Scotto G, Turinetti M, Biglia N, Fuso L, Mariani L, Franchi D, Vidal Urbinati AM, Pino I, Bertschy G, Preti M, Benedetto C, Castellano I, Cassoni P, **Bertero L**. Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers. **Ann Surg Oncol**. 2022 Dec;29(13):8302-8314. doi: 10.1245/s10434-022-12353-y. Epub 2022 Aug 17.
  14. Borella F, Benedetto C, Cassoni P, **Bertero L**. ASO Author Reflections: Surgical Management and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): New Insights. **Ann Surg Oncol**. 2022 Dec;29(13):8315-8316. doi: 10.1245/s10434-022-12426-y. Epub 2022 Aug 17.
  15. Borella F, **Bertero L**, Cassoni P, Piovano E, Gallio N, Preti M, Cosma S, Ferraioli D, Pace L, Mariani L, Biglia N, Benedetto C. Low-Grade Uterine Endometrial Stromal Sarcoma: Prognostic Analysis of Clinico-Pathological Characteristics, Surgical Management, and Adjuvant Treatments. Experience From Two Referral Centers. **Front Oncol**. 2022 Jun 30;12:883344. doi: 10.3389/fonc.2022.883344.
  16. Boffini M, Cassoni P, Gambella A, Simonato E, Delsedime L, Marro M, Fanelli V, Costamagna A, Lausi PO, Solidoro P, Scalini F, Barbero C, Brazzi L, Rinaldi M, **Bertero L**. Is there life on the airway tree? A pilot study of bronchial cell vitality and tissue morphology in the ex vivo lung perfusion (EVLV) era of lung transplantation. **Artif Organs**. 2022 Nov;46(11):2234-2243. doi: 10.1111/aor.14342.
  17. Borella F, Preti M, Vieira-Baptista P, Pérez-López FR, **Bertero L**, Gallio N, Micheletti L, Benedetto C. Vulvar Paget's disease: outcomes of 51 patients treated with imiquimod cream. **Maturitas**. 2022 Sep;163:23-27. doi: 10.1016/j.maturitas.2022.05.010.
  18. Bruno F, Pellerino A, Pronello E, Palmiero R, **Bertero L**, Mantovani C, Bianconi A, Melcarne A, Garbossa D, Rudà R. Elderly Glioblastoma Patients: The Impact of Surgery and Adjuvant Treatments on Survival: A Single Institution Experience. **Brain Sci**. 2022 May 11;12(5):632. doi: 10.3390/brainsci12050632.
  19. Pellerino A, Bruno F, Palmiero R, Pronello E, **Bertero L**, Soffietti R, Rudà R. Clinical Significance of Molecular Alterations and Systemic Therapy for Meningiomas: Where Do We Stand? **Cancers (Basel)**. 2022 Apr 30;14(9):2256. doi: 10.3390/cancers14092256.
  20. Borella F, Cosma S, Ferraioli D, Preti M, Gallio N, Valabrega G, Scotto G, Rolfo A, Castellano I, Cassoni P, **Bertero L**, Benedetto C. From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia. **Front Oncol**. 2022 Apr 13;12:859071. doi: 10.3389/fonc.2022.859071.
  21. Monteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, de Pablos-Aragoneses A, Yebra N, Retana D, Baena P, Fustero-Torre C, Graña-Castro O, Trolé K, Caleiras E, Tezanos P, Muela P, Cintado E, Trejo JL, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Lain A, Mazarico Gallego J, Ferrer I, Suárez R, Garrido-Martín EM, Paz-Ares L, Dalmasso C, Cohen-Jonathan Moyal E, Siegfried A, Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, **Bertero L**, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martín SM, Gonzalez A, Adler O, Erez N; RENACER, Valiente M. Stratification of radiosensitive brain

- metastases based on an actionable S100A9/RAGE resistance mechanism. **Nat Med.** 2022 Apr 11. doi: 10.1038/s41591-022-01749-8.
22. Trucco G, Chiusa L, Tandoi F, **Bertero L.** First report of a gallbladder hemangioma coexisting with gallstones: a case report and literature review of a rare finding. **BMC Surg.** 2022 Apr 6;22(1):128. doi: 10.1186/s12893-022-01554-7.
  23. Bruno F, Pellerino A, Palmiero R, **Bertero L,** Mantovani C, Garbossa D, Soffiatti R, Rudà R. Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects. **Biomedicines.** 2022 Mar 10;10(3):644. doi: 10.3390/biomedicines10030644.
  24. Gambella A, Falco EC, Benazzo G, Osella-Abate S, Senetta R, Castellano I, **Bertero L,** Cassoni P. The Importance of Being "That" Colorectal pT1: A Combined Clinico-Pathological Predictive Score to Improve Nodal Risk Stratification. **Front Med (Lausanne).** 2022 Feb 14;9:837876. doi: 10.3389/fmed.2022.837876.
  25. Zhu L, Retana D, García-Gómez P, Álvaro-Espinosa L, Priego N, Masmudi-Martín M, Yebra N, Miarka L, Hernández-Encinas E, Blanco-Aparicio C, Martínez S, Sobrino C, Ajenjo N, Artiga MJ, Ortega-Paino E, Torres-Ruiz R, Rodríguez-Perales S; RENACER, Soffiatti R, **Bertero L,** Cassoni P, Weiss T, Muñoz J, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Laín A, Toldos O, Ruano Y, Alcázar L, Blasco G, Fernández-Alén J, Caleiras E, Lafarga M, Megías D, Graña-Castro O, Nör C, Taylor MD, Young LS, Varešlija D, Cosgrove N, Couch FJ, Cussó L, Desco M, Mouron S, Quintela-Fandino M, Weller M, Pastor J, Valiente M. A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. **EMBO Mol Med.** 2022 Mar 7;14(3):e14552. doi: 10.15252/emmm.202114552.
  26. Micheletti L, Borella F, Preti M, Frau V, Cosma S, Privitera S, **Bertero L,** Benedetto C. Perineural Invasion in Vulvar Squamous-Cell Carcinoma Is an Independent Risk Factor for Cancer-Specific Survival, but Not for Locoregional Recurrence: Results from a Single Tertiary Referral Center. **Cancers (Basel).** 2021 Dec 28;14(1):124. doi: 10.3390/cancers14010124.
  27. Faletti S, Osti D, Ceccacci E, Richichi C, Costanza B, Nicosia L, Noberini R, Marotta G, Furia L, Faretta MR, Brambillasca S, Quarto M, **Bertero L,** Boldorini R, Pollo B, Gandini S, Cora D, Minucci S, Mercurio C, Varasi M, Bonaldi T, Pelicci G. LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response. **Sci Transl Med.** 2021 Dec 8;13(623):eabf7036. doi: 10.1126/scitranslmed.abf7036.
  28. Vissio E, Falco EC, Scozzari G, Scarmozzino A, Trinh DAA, Morino M, Papotti M, **Bertero L,** Cassoni P. The Adverse Impact of the COVID-19 Pandemic on Abdominal Emergencies: A Retrospective Clinico-Pathological Analysis. **J Clin Med.** 2021 Nov 11;10(22):5254. doi: 10.3390/jcm10225254.
  29. Cosma S, Carosso AR, Cusato J, Borella F, **Bertero L,** Bovetti M, Bevilacqua F, Mengozzi G, Mazzone R, Ghisetti V, Di Perri G, Benedetto C. Obstetric and neonatal outcomes after SARS-CoV-2 infection in the first trimester of pregnancy: A prospective comparative study. **J Obstet Gynaecol Res.** 2022 Feb;48(2):393-401. doi: 10.1111/jog.15105.
  30. Mirian C, Grell K, Juratli TA, Sahm F, Spiegl-Kreinecker S, Peyre M, Biczok A, Tonn JC, Goutagny S, **Bertero L,** Maier AD, Jensen LR, Schackert G, Broholm H, Scheie D, Cahill DP, Brastianos PK, Skjøth-Rasmussen J, Fugleholm K, Ziebell M, Munch TN, Kristensen BW, Mathiesen T. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma. **Neuropathol Appl Neurobiol.** 2022 Apr;48(3):e12773. doi: 10.1111/nan.12773.
  31. Franchino F, Morra I, Forni M, **Bertero L,** Zanini C, Roveta F, Ricardi U, Mantovani C, Carpaneto A, Migliore E, Pellerino A, Ferrio F, Cassoni P, Garbossa D, Soffiatti R, Ruda' R. Medulloblastoma in adults: an analysis of clinico-pathological, molecular and treatment factors. **J Neurosurg Sci.** 2021 Nov 11. doi: 10.23736/S0390-5616.21.05548-X.
  32. Gambella A, Barreca A, Osella-Abate S, Bottasso E, Giarin MM, Papotti M, Biancone L, Metovic J, Collelli G, Cassoni P, **Bertero L.** Caveolin-1 in Kidney Chronic

- Antibody-Mediated Rejection: An Integrated Immunohistochemical and Transcriptomic Analysis Based on the Banff Human Organ Transplant (B-HOT) Gene Panel. **Biomedicines**. 2021 Sep 26;9(10):1318. doi: 10.3390/biomedicines9101318.
33. Rudà R, Bruno F, Ius T, Silvani A, Minniti G, Pace A, Lombardi G, **Bertero L**, Pizzolitto S, Pollo B, Conti Nibali M, Pellerino A, Migliore E, Skrap M, Bello L, Soffietti R. IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups. **Neuro Oncol**. 2021 Oct 15: noab239. doi: 10.1093/neuonc/noab239. Online ahead of print.
  34. Gao Y, Wei L, Kim SJ, Wang L, He Y, Zheng Y, **Bertero L**, Pellerino A, Cassoni P, Tamagnone L, Theresa PK, Deutsch A, Zhan H, Lai J, Wang Y, You H. A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups. **Front Oncol**. 2021 Aug 3;11:696147. doi: 10.3389/fonc.2021.696147. eCollection 2021.
  35. Bruno F, Pellerino A, **Bertero L**, Soffietti R, Rudà R. Targeted Therapies in Rare Brain Tumours. **Int J Mol Sci**. 2021 Jul 26;22(15):7949. doi: 10.3390/ijms22157949.
  36. Preti M, Borella F, Gallio N, **Bertero L**, Heller DS, Vieira-Baptista P, Cosma S, Bevilacqua F, Privitera S, Micheletti L, Benedetto C. Superficially Invasive Vulvar Squamous Cell Carcinoma: A 37-Year-Long Experience of a Tertiary Referral Center. **Cancers (Basel)**. 2021 Jul 31;13(15):3859. doi: 10.3390/cancers13153859.
  37. Specchia FMC, Monticelli M, Zeppa P, Bianconi A, Zenga F, Altieri R, Pugliese B, Di Perna G, Cofano F, Tartara F, **Bertero L**, Cassoni P, Melcarne A, Lanotte MM, Garbossa D. Let Me See: Correlation between 5-ALA Fluorescence and Molecular Pathways in Glioblastoma: A Single Center Experience. **Brain Sci**. 2021 Jun 16;11(6):795. doi: 10.3390/brainsci11060795.
  38. **Bertero L**, Gambella A, Barreca A, Osella-Abate S, Chiusa L, Francia di Celle P, Lista P, Papotti M, Cassoni P. Caveolin-1 expression predicts favourable outcome and correlates with PDGFRA mutations in gastrointestinal stromal tumours (GISTs). **J Clin Pathol**. 2021 Jun 21; jclinpath-2021-207595. doi: 10.1136/jclinpath-2021-207595. Online ahead of print.
  39. Metovic J, Bragoni A, Osella-Abate S, Borella F, Benedetto C, Gualano MR, Olivero E, Scaioli G, Siliquini R, Ferrando PM, **Bertero L**, Sapino A, Cassoni P, Castellano I. Clinical Relevance of Tubular Breast Carcinoma: Large Retrospective Study and Meta-Analysis. **Front Oncol**. 2021 Apr 29;11:653388. doi: 10.3389/fonc.2021.653388. eCollection 2021.
  40. **Bertero L**, Borella F, Botta G, Carosso A, Cosma S, Bovetti M, Carosso M, Abbona G, Collelli G, Papotti M, Cassoni P, Benedetto C. Placenta histopathology in SARS-CoV-2 infection: analysis of a consecutive series and comparison with control cohorts. **Virchows Arch**. 2021 May 1:1-14. doi: 10.1007/s00428-021-03097-3. Online ahead of print.
  41. Tonella L, Pala V, Ponti R, Rubatto M, Gallo G, Mastorino L, Avallone G, Merli M, Agostini A, Fava P, **Bertero L**, Senetta R, Osella-Abate S, Ribero S, Fierro MT, Quaglino P. Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications. **Int J Mol Sci**. 2021 Apr 27;22(9):4561. doi: 10.3390/ijms22094561.
  42. **Bertero L**, Righi L, Collelli G, Koelsche C, Hou Y, Stichel D, Schrimpf D, Flucke U, Petersen I, Vokuhl C, Fröhling S, Bironzo P, Scagliotti GV, Cassoni P, Papotti M, von Deimling A. DNA methylation profiling discriminates between malignant pleural mesothelioma and neoplastic or reactive histological mimics. **J Mol Diagn**. 2021 Apr 19:S1525-1578(21)00090-8. doi: 10.1016/j.jmoldx.2021.04.002.
  43. Baldassarre BM, Penner F, **Bertero L**, Di Perna G, Ajello M, Marengo N, Zenga F, Garbossa D. Solitary late spinal metastasis from apocrine salivary duct carcinoma: Case report. **Surg Neurol Int**. 2021 Mar 30;12:122. doi: 10.25259/SNI\_903\_2020. eCollection 2021.
  44. Borella F, Carosso AR, Cosma S, Preti M, Collelli G, Cassoni P, **Bertero L**, Benedetto C. Gut Microbiota and Gynecological Cancers: A Summary of

- Pathogenetic Mechanisms and Future Directions. **ACS Infect Dis**. 2021 Apr 13. doi: 10.1021/acscinfecdis.0c00839.
45. Metovic J, Abate SO, Borella F, Vissio E, **Bertero L**, Mariscotti G, Durando M, Senetta R, Ala A, Benedetto C, Sapino A, Cassoni P, Castellano I. The lobular neoplasia enigma: management and prognosis in a long follow-up case series. **World J Surg Oncol**. 2021 Mar 18;19(1):80. doi: 10.1186/s12957-021-02182-w.
  46. Buccoliero AM, Caporalini C, Scagnet M, Mussa F, Giordano F, Sardi I, Migliastro I, Moscardi S, Conti V, Barba C, Antonelli M, Gianni F, Rossi S, Diomedi-Camassei F, Gessi M, Donofrio V, **Bertero L**, Giangaspero F, Santi M, Aronica E, Genitori L, Guerrini R. Angiocentric glioma-associated seizures: The possible role of EATT2, pyruvate carboxylase and glutamine synthetase. **Seizure**. 2021 Mar;86:152-154. doi: 10.1016/j.seizure.2021.02.014.
  47. Perna GD, Cofano F, Altieri R, Baldassarre BM, **Bertero L**, Zenga F, Garbossa D. III cranial nerve cavernous malformation: A case report and review of the literature. **Surg Neurol Int**. 2020 Dec 22;11:452. doi: 10.25259/SNI\_650\_2020. eCollection 2020.
  48. Pronello E, Mo F, Gottardi D, Palmiero R, **Bertero L**, Lanotte M, Ferrio MF, Rudà R, Soffietti R. Richter's Syndrome of the Central Nervous System. **Can J Neurol Sci**. 2021 Jan 5:1-4. doi: 10.1017/cjn.2020.281.
  49. Borella F, Preti M, **Bertero L**, Collelli G, Castellano I, Cassoni P, Cosma S, Carosso AR, Bevilacqua F, Gallio N, Benedetto C, Micheletti L. Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review. **Int J Mol Sci**. 2020 Dec 27;22(1):190. doi: 10.3390/ijms22010190.
  50. Vissio E, Falco EC, Collelli G, Borella F, Papotti M, Scarmozzino A, Cassoni P, **Bertero L**. Reply to: Oncologic thoracic surgery during the second wave of COVID-19 pandemic: How to be ready for the storm. **J Surg Oncol**. 2021 Mar;123(4):1169. doi: 10.1002/jso.26334.
  51. Vissio E, Falco EC, Collelli G, Borella F, Papotti M, Scarmozzino A, Cassoni P, **Bertero L**. Impact of COVID-19 lockdown measures on oncological surgical activity: Analysis of the surgical pathology caseload of a tertiary referral hospital in Northwestern Italy. **J Surg Oncol**. 2021 Jan;123(1):24-31. doi: 10.1002/jso.26256.
  52. Borella F, **Bertero L**, Morrone A, Gambella A, Bovetti M, Cosma S, Carosso A, Katsaros D, Gemmiti S, Preti M, Valabrega G, Scotto G, Cassoni P, Benedetto C. Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis. **Cancers (Basel)**. 2020 Aug 4;12(8):2156. doi: 10.3390/cancers12082156.
  53. Osella-Abate S, Vignale C, Annaratone L, Nocifora A, **Bertero L**, Castellano I, Avallone G, Conti L, Quaglino P, Picciotto F, Senetta R, Papotti MG, Cassoni P, Ribero S. Microenvironment in cutaneous melanomas: a gene expression profile study may explain the role of histological regression. **J Eur Acad Dermatol Venereol**. 2021 Jan;35(1):e35-e38. doi: 10.1111/jdv.16784.
  54. Metovic J, Annaratone L, Linari A, Osella-Abate S, Musuraca C, Veneziano F, Vignale C, **Bertero L**, Cassoni P, Ratto N, Comandone A, Grignani G, Piana R, Papotti M. Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone. **Cancer Immunol Immunother**. 2020 Sep;69(9):1905-1916. doi: 10.1007/s00262-020-02594-9.
  55. **Bertero L**, Spadi R, Osella-Abate S, Mariani S, Castellano I, Gambella A, Racca P, Morino M, Cassoni P. Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit. **World J Surg Oncol**. 2020 Apr 2;18(1):65. doi: 10.1186/s12957-020-01844-5.
  56. Mirian C, Duun-Henriksen AK, Juratli T, Sahm F, Spiegl-Kreinecker S, Peyre M, Biczok A, Tonn JC, Goutagny S, **Bertero L**, Maier AD, Møller Pedersen M, Law I, Broholm H, Cahill DP, Brastianos P, Poulsgaard L, Fugleholm K, Ziebell M, Munch T, Mathiesen T. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data

- meta-analysis. **J Neurol Neurosurg Psychiatry**. 2020 Feb 10. pii: jnnp-2019-322257. doi: 10.1136/jnnp-2019-322257.
57. Bruno F, Pellerino A, **Bertero L**, Soffietti R, Rudà R. Long-term survival of a sacrococcygeal myxopapillary ependymoma with extra-neural metastases: case report and review of the literature. **Neurol Sci**. 2020 Jan 28. doi: 10.1007/s10072-020-04269-w.
  58. Gambella A, Senetta R, Collelli G, Vallero SG, Monticelli M, Cofano F, Zeppa P, Garbossa D, Pellerino A, Rudà R, Soffietti R, Fagioli F, Papotti M, Cassoni P, **Bertero L**. NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. **Int J Mol Sci**. 2020 Jan 23;21(3). pii: E753. doi: 10.3390/ijms21030753.
  59. Pellerino A, **Bertero L**, Rudà R, Soffietti R. Choosing appropriate chemotherapy for diffusely infiltrating WHO grade II gliomas in adults. **Expert Opin Pharmacother**. 2020 Jan 20:1-3. doi: 10.1080/14656566.2020.1714030.
  60. Cofano F, Monticelli M, Ajello M, Zenga F, Marengo N, Di Perna G, Altieri R, Cassoni P, **Bertero L**, Melcarne A, Tartara F, Ducati A, Garbossa D. The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. **Cancer Control**. 2019 Jan-Dec;26(1):1073274819870549. doi: 10.1177/1073274819870549.
  61. Vissio E, Metovic J, Osella-Abate S, **Bertero L**, Migliaretti G, Borella F, Benedetto C, Sapino A, Cassoni P, Castellano I. Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling. **Br J Cancer**. 2019 Nov 29. doi: 10.1038/s41416-019-0656-6.
  62. Cosma S, Borella F, Carosso A, Ingala A, Fassio F, Robba T, Maina A, **Bertero L**, Benedetto C. Osteomyelitis of the pubic symphysis caused by methicillin-resistant *Staphylococcus aureus* after vaginal delivery: a case report and literature review. **BMC Infect Dis**. 2019 Nov 8;19(1):952. doi: 10.1186/s12879-019-4595-x.
  63. Deli F, Romano F, Gualini G, Mariani GM, Sala I, Veneziano F, **Bertero L**, Cassoni P, Aimetti M. Resident memory T cells: Possible players in periodontal disease recurrence. **J Periodontol Res**. 2019. doi:10.1111/jre.12709
  64. Rudà R, Pellerino A, Pace A, Carapella CM, Dealis C, Caroli M, Faedi M, Bello L, Migliore E, Marchese G, **Bertero L**, Cassoni P, Soffietti R. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. **J Neurooncol**. 2019;145(1):115–123. doi:10.1007/s11060-019-03277-x
  65. Borella F, Lucchino F, **Bertero L**, Ribotta M, Castellano I, Carosso A, Cosma S, Katsaros D, Benedetto C. Clinico-pathological features of gynecological myopericytoma: a challenging diagnosis in an exceptional location. **Virchows Arch**. 2019 Aug 13. doi: 10.1007/s00428-019-02645-2.
  66. Osella-Abate S, Conti L, Annaratone L, Senetta R, **Bertero L**, Licciardello M, Caliendo V, Picciotto F, Quagliano P, Cassoni P, Ribero S. Phenotypic characterisation of immune cells associated with histological regression in cutaneous melanoma. **Pathology**. 2019 Aug;51(5):487-493. doi: 10.1016/j.pathol.2019.04.001.
  67. **Bertero L**, Siravegna G, Rudà R, Soffietti R, Bardelli A, Cassoni P. Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours. **Neuropathol Appl Neurobiol**. 2019 Apr 12. doi: 10.1111/nan.12553.
  68. Hou Y, Pinheiro J, Sahm F, Reuss DE, Schrimpf D, Stichel D, Casalini B, Koelsche C, Sievers P, Wefers AK, Reinhardt A, Ebrahimi A, Francisco F, Pusch S, Paulus W, Prinz M, Hartmann C, Plate K, Reifenberger G, Schüller U, Scheie D, de Stricker K, Hench J, Pollo B, Brandner S, Unterberg A, Meier J, Pfister S, Jones D, Korshunov A, Wick W, Capper D, Blümcke I, von Deimling A, **Bertero L**. Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving *PRKCA*. **Acta Neuropathol**. 2019 May;137(5):837-846. doi: 10.1007/s00401-019-01969-2.
  69. Osella-Abate S, **Bertero L**, Senetta R, Mariani S, Lisa F, Coppola V, Metovic J, Pasini B, Puig S S, Fierro MT, Manrique-Silva E, Kumar R, Nagore E, Cassoni P, Ribero S. TERT Promoter Mutations are Associated with Visceral Spreading in



- Melanoma of the Trunk. **Cancers (Basel)**. 2019 Mar 30;11(4). pii: E452. doi: 10.3390/cancers11040452.
70. **Bertero L**, Dalla Dea G, Osella-Abate S, Botta C, Castellano I, Morra I, Pollo B, Calatozzolo C, Patriarca S, Mantovani C, Rudà R, Tardivo V, Zenga F, Garbossa D, Papotti M, Soffietti R, Ricardi U, Cassoni P. Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. **J Neuropathol Exp Neurol**. 2019 Mar 1;78(3):248-256. doi: 10.1093/jnen/nly127
  71. **Bertero L**, Joseph SB, Trunfio M, Alice T, Catera S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, Ghisetti V, Amasio E, Zanusso G, Bonora S, Di Perri G, Calcagno A. HIV-1 detection in the olfactory mucosa of HIV-1 infected participants. **AIDS**. 2019 Mar 15;33(4):665-674. doi: 10.1097/QAD.0000000000002102.
  72. Mellai M, Annovazzi L, Boldorini R, **Bertero L**, Cassoni P, De Blasio P, Biunno I, Schiffer D. SEL1L Plays a Major Role in Human Malignant Gliomas. **J Pathol Clin Res**. 2019 May 20. doi: 10.1002/cjp2.134.
  73. Cofano F, Marengo N, Pecoraro F, Penner F, **Bertero L**, Zenga F. Spinal epidural capillary hemangioma: case report and review of the literature. **Br J Neurosurg**. 2019 4:1-4. doi: 10.1080/02688697.2018.1562034.
  74. Ribero S, Galli F, Osella-Abate S, **Bertero L**, Cattaneo L, Merelli B, Tondini C, Ghilardi L, De Giorgi V, Ocelli M, Quaglino P, Cassoni P, Palmieri G, Massi D, Mandala M; Italian Melanoma Intergroup. Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness. **J Am Acad Dermatol**. 2019 Jan;80(1):99-105.e5. doi: 10.1016/j.jaad.2018.06.054.
  75. Osella-Abate S, Mereu E, Pellegrino E, Bergaggio E, Ribero S, **Bertero L**, Lisa F, Fierro MT, Giulio Papotti M, Piva R. ALK expression favorably impacts the prognosis of *NRAS*-mutated metastatic melanomas. **Oncol Lett**. 2018 Dec;16(6):7091-7096. doi: 10.3892/ol.2018.9560.
  76. **Bertero L**, Anfossi V, Osella-Abate S, Disanto MG, Mantovani C, Zenga F, Rudà R, Garbossa D, Soffietti R, Ricardi U, Papotti M, Cassoni P. Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. **PLoS One**. 2018 Sep 5;13(9):e0203570. doi: 10.1371/journal.pone.0203570.
  77. Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, Doglio L, Martínez L, Martínez-Saez E, Cajal SRY, Megías D, Hernández-Encinas E, Blanco-Aparicio C, Martínez L, Zarzuela E, Muñoz J, Fustero-Torres C, Pineiro E, Hernández-Laín A, **Bertero L**, Poli V, Sánchez-Martínez M, Menendez JA, Soffietti R, Bosch-Barrera J, Valiente M. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. **Nat Med**. 2018 Jul;24(7):1024-1035. doi: 10.1038/s41591-018-0044-4.
  78. Koelsche C, Mynarek M, Schrimpf D, **Bertero L**, Serrano J, Sahn F, Reuss DE, Hou Y, Baumhoer D, Vokuhl C, Flucke U, Petersen I, Brück W, Rutkowski S, Zambrano SC, Garcia Leon JL, Diaz Coronado RY, Gessler M, Tirado OM, Mora J, Alonso J, Garcia Del Muro X, Esteller M, Sturm D, Ecker J, Milde T, Pfister SM, Korshunov A, Snuderl M, Mechttersheimer G, Schüller U, Jones DTW, von Deimling A. Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. **Acta Neuropathol**. 2018 Aug;136(2):327-337. doi: 10.1007/s00401-018-1871-6.
  79. Metovic J, **Bertero L**, Musuraca C, Veneziano F, Annaratone L, Mariani S, Cassoni P, Bussolati G, Papotti M. Safe transportation of formalin-fixed liquid-free pathology specimens. **Virchows Arch**. 2018 Jul;473(1):105-113. doi: 10.1007/s00428-018-2383-4.
  80. Mariani S, **Bertero L**, Coppola V, Saracco G, Arezzo A, Francia Di Celle P, Metovic J, Marchiò C, Cassoni P. Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices. **Expert Rev Mol Diagn**. 2018 May;18(5):467-475. doi: 10.1080/14737159.2018.1468254.
  81. **Bertero L**, Massa F, Metovic J, Zanetti R, Castellano I, Ricardi U, Papotti M, Cassoni P. Eighth Edition of the UICC Classification of Malignant Tumours: an overview of

- the changes in the pathological TNM classification criteria-What has changed and why? **Virchows Arch**. 2018 Apr;472(4):519-531. doi: 10.1007/s00428-017-2276-y.
82. Schiffer D, Mellai M, Boldorini R, Bisogno I, Grifoni S, Corona C, **Bertero L**, Cassoni P, Casalone C, Annovazzi L. The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas. **Int J Mol Sci**. 2018 Sep 12;19(9). pii: E2724. doi: 10.3390/ijms19092724.
  83. Monticelli M, Zeppa P, Zenga F, Altieri R, Mammi M, **Bertero L**, Castellano I, Cassoni P, Melcarne A, La Rocca G, Sabatino G, Ducati A, Garbossa D. The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review. **Clin Neurol Neurosurg**. 2018 Jul;170:120-126. doi: 10.1016/j.clineuro.2018.05.015.
  84. Tardivo V, Vincitorio F, Monticelli M, **Bertero L**, Zenga F, Ducati A, Cassoni P, Garbossa D. Double cystic brain metastasis in a patient with stable pancreatic intraductal papillary mucinous neoplasm. **Br J Neurosurg**. 2018 Mar 20:1-5. doi: 10.1080/02688697.2018.1451824.
  85. Pellerino A, **Bertero L**, Rudà R, Soffietti R. Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. **Ther Adv Neurol Disord**. 2018 Mar 7;11:1756286418759618. doi: 10.1177/1756286418759618.
  86. Radin M, **Bertero L**, Roccatello D, Sciascia S. Severe Multi-Organ Failure and Hypereosinophilia: When to Call It "Idiopathic"? **J Investig Med High Impact Case Rep**. 2018 Feb 15;6:2324709618758347. doi: 10.1177/2324709618758347.
  87. Rangel N, Rondon-Lagos M, Annaratone L, Osella-Abate S, Metovic J, Mano MP, **Bertero L**, Cassoni P, Sapino A, Castellano I. The role of the AR/ER ratio in ER-positive breast cancer patients. **Endocr Relat Cancer**. 2018 Mar;25(3):163-172. doi: 10.1530/ERC-17-0417.
  88. Rrapaj E, Trisolini E, **Bertero L**, Salvo M, Indelicato R, Andorno S, Garcia-Manteiga JM, Rena O, Boldorini RL. Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma. **Histopathology**. 2018 May;72(6):1039-1050. doi: 10.1111/his.13470.
  89. **Bertero L**, Zenga F, Maletta F, Senetta R, Cassoni P. A 68-Year-Old Woman with A Left Orbital and Temporal Mass. **Brain Pathol**. 2018 Jan;28(1):133-134. doi: 10.1111/bpa.12580.
  90. Rossi G, **Bertero L**, Marchiò C, Papotti M. Molecular alterations of neuroendocrine tumours of the lung. **Histopathology**. 2018 Jan;72(1):142-152. doi: 10.1111/his.13394.
  91. Pellerino A, Rudà R, **Bertero L**, Magistrello M, Franchino F, Cassoni P, Pasqualetti F, Pinessi L, Giangaspero F, Soffietti R. Successful use of bevacizumab in an adult primary diffuse leptomeningeal glioneuronal tumor. **J Neurosurg Sci**. 2018 Apr;62(2):229-232. doi: 10.23736/S0390-5616.16.03804-2.
  92. Conti L, Vatrano S, **Bertero L**, Masu L, Pacchioni D, Daniele L, De Rosa G, Cassoni P, Volante M, Papotti M. Mitochondrial DNA "common deletion" in post-fine needle aspiration infarcted oncocyctic thyroid tumors. **Hum Pathol**. 2017 Nov;69:23-30. doi: 10.1016/j.humpath.2017.09.004.
  93. Mariani S, **Bertero L**, Osella-Abate S, Di Bello C, Francia di Celle P, Coppola V, Sapino A, Cassoni P, Marchiò C. Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. **Br J Cancer**. 2017 Jul 25;117(3):358-366. doi: 10.1038/bjc.2017.170.
  94. Marchiò C, Gatti G, Massa F, **Bertero L**, Filosso P, Pelosi G, Cassoni P, Volante M, Papotti M. Distinctive pathological and clinical features of lung carcinoids with high proliferation index. **Virchows Arch**. 2017 Dec;471(6):713-720. doi: 10.1007/s00428-017-2177-0. I
  95. Duregon E, Senetta R, **Bertero L**, Bussolati B, Annaratone L, Pittaro A, Papotti M, Marchiò C, Cassoni P. Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas. **Tumour Biol**. 2017 Feb;39(2):1010428317694311. doi: 10.1177/1010428317694311.

96. Marchiò C, Mariani S, **Bertero L**, Di Bello C, Francia Di Celle P, Papotti M, Rudà R, Soffietti R, Cassoni P. Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. **Neuro Oncol.** 2017 Mar 1;19(3):451-453. doi: 10.1093/neuonc/now244.
97. Duregon E, **Bertero L**, Pittaro A, Soffietti R, Rudà R, Trevisan M, Papotti M, Ventura L, Senetta R, Cassoni P. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. **Oncotarget.** 2016;7(16):21190-21198. doi: 10.18632/oncotarget.8498.
98. Senetta R, Mellai M, Manini C, Castellano I, **Bertero L**, Pittaro A, Schiffer D, Boldorini R, Cassoni P. Mesenchymal/radioresistant traits in granular astrocytomas: evidence from a combined clinical and molecular approach. **Histopathology.** 2016;69(2):329-337. doi: 10.1111/his.12944.
99. Castellano A, Donativi M, Rudà R, De Nunzio G, Riva M, Iadanza A, **Bertero L**, Rucco M, Bello L, Soffietti R, Falini A. Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps. **Eur Radiol.** 2016;26(5):1263-1273.
100. Trevisan E, **Bertero L**, Magistrello M, Rudà R, Soffietti R. Is there a role for bevacizumab in non-glioma tumors? **Curr Drug Targets.** 2015;16(7):684-688.
101. **Bertero L**, Cassoni P, Rudà R. Nocardia abscesses mimicking tumor progression in gliomatosis cerebri responding to temozolomide. **J Neurooncol.** 2015;121(1):225-227. doi: 10.1007/s11060-014-1609-9.
102. Soffietti R, **Bertero L**, Pinessi L, Rudà R. Pharmacologic therapies for malignant glioma: a guide for clinicians. **CNS Drugs.** 2014;18(12):1127-1137. doi: 10.1007/s40263-014-0215-x.
103. Trevisan R, **Bertero L**, Bosa C, Magistrello M, Pellerino A, Rudà R, Soffietti R. Antiangiogenic therapy of brain tumors: the role of bevacizumab. **Neurol Sci.** 2014;35(4):507-514. doi: 10.1007/s40263-014-0215-x.
104. Rudà R, **Bertero L**, Sanson M. Gliomatosis cerebri: a review. **Curr Treat Options Neurol.** 2014;16(2):273.
105. Soffietti R, Trevisan E, **Bertero L**, Cassoni P, Morra I, Fabrini MG, Pasqualetti F, Lolli I, Castiglione A, Ciccone G, Rudà R. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). **J Neurooncol.** 2014;116(3):533-541.
106. Simonetti G, Trevisan E, Silvani A, Gaviani P, Botturi A, Lamperti E, Beecher D, **Bertero L**, Bosa C, Salmaggi A. Safety of bevacizumab in patients with malignant gliomas: a systematic review. **Neurol Sci.** 2014;35(1):83-89.
107. Rudà R, Magliola U, **Bertero L**, Trevisan E, Bosa C, Mantovani C, Ricardi U, Castiglione A, Monagheddu C, Soffietti R. Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. **Neuro Oncol.** 2013;15(12):1739-1749.
108. Soffietti R, Trevisan E, **Bertero L**, Bosa C, Rudà R. Anti-angiogenic approaches to malignant gliomas. **Curr Cancer Drug Targets.** 2012 Mar;12(3):279-288.
109. Cavanna AE, Cavanna S, **Bertero L**, Robertson MM. Depression in women with epilepsy: clinical and neurobiological aspects. **Funct Neurol.** 2009 Apr-Jun;24(2):83-7.
110. Cavanna AE, **Bertero L**, Cavanna S, Servo S, Strigaro G, Monaco F. Persistent akinetic mutism after bilateral paramedian thalamic infarction. **J Neuropsychiatry Clin Neurosci.** 2009 Summer;21(3):351.

#### Book chapters

- Cassoni P, **Bertero L**. Curatela Capitolo 28 – Il Sistema Nervoso Centrale. In: Kumar M., Abbas AK, Aster JC (eds.), **Robbins e Cotran – Le basi patologiche delle malattie**. Milano: Edra; 2021. Pp: 1211-1272. ISBN: 9788821455629.
- **Bertero L**, Cassoni P. Classification of Tumours of the Central Nervous System. In: Bartolo M, Soffietti R and Klein M (eds.), **Neurorehabilitation in Neuro-Oncology**. Cham: Springer; 2019. Pp: 21-36. ISBN: 9783319956848.

- **Bertero L**, Cassoni P. Patologia del sistema nervoso centrale – Tumori. In: D’Amati G and Della Rocca C (eds.), **Gallo d’Amati. Anatomia Patologica. La sistematica**. Milano: Edra; 2018.
- Soffietti R, Rudà R, **Bertero L**, Trevisan E, Bosa C, Morra I. Neoplasie del sistema nervoso centrale. In: R. Labianca and S. Cascinu (eds.), **La Medicina Oncologica. Diagnosi, terapia e gestione clinica**. Milano: Edra; 2013.
- Rudà R, **Bertero L**, Soffietti R. Natural history and spontaneous prognostic factors. In: Duffau H (ed.), **Diffuse low-grade gliomas in adults**. London: Springer; 2013.
- Soffietti R, Bosa C, **Bertero L**, Rudà R. Whole brain radiotherapy: impact of the EORTC trial for treatment decisions. In Boiron M and Marty M (eds.), **Eurocancer 2011**. Montrouge: John Libbey Eurotext; 2011.

## Invited relations to international meetings

- Advances in brain tumor classification, by methylation analysis. Swiss Italian Neuro-Oncology Meeting 2022. Lugano, 27th October 2022.
- From H&E to pixels: digital pathology applications for colon cancer diagnosis. H2020 DeepHealth Project Winter School. Online, 25th January 2022.
- Joint Slide Seminar with Short Talks Soft Tissue and Bone Pathology – Case 3. Neuropathology: CNS and bone/soft tissue tumours: the beauty and the beast. 33rd European Congress of Pathology. Online, 31st August 2021.
- Intra-axial primary brain tumors – Neuropathology: Current WHO classification (2016). ESO Masterclass in Neuro-Oncology: multidisciplinary management of adult brain tumours. Online, 11th-13th December 2020.
- La diagnosi dei tumori nel terzo millennio fra istopatologia e biologia molecolare. Neuro Onco Forum 2019. Lugano, Switzerland, 17th October 2019.
- Intra-axial primary brain tumors: high grade gliomas and lower grade gliomas. Neuropathology: Current WHO classification (2016). ESO Masterclass in Neuro-oncology: Multidisciplinary management of adult brain tumour. Milan, Italy, 20th-22nd September 2018.
- The potential role of liquid biopsy. Swiss-Italian Neuro-Oncology Meeting: Advances and controversies in Neuro-Oncology. Turin, Italy, 29th-30th September 2017.
- Pathology and molecular biology: The way to improved treatment selection and the modern strategy in trial design. ESO-EANO Masterclass in Neuro-Oncology: Challenges in Radiotherapy for Patients with Gliomas. Lugano, Switzerland, 15th-17th September 2016.
- Gliomatosis cerebri. Swiss Italian Neuro Oncology Meeting 2013. Lugano, Switzerland, 5th-7th September 2013.

## Invited relations to national (Italian) meetings

- Diagnosi integrata istologico-molecolare nell’ependimoma e nel medulloblastoma. XXV Congresso Nazionale dell’Associazione Italiana di Neuro-Oncologia (AINO). Padova, Italy, 10 November 2022.
- Teacher “Basic Neuropathology Course” – Scuola Nazionale di Specializzazione in Anatomia Patologica. Topics: glioblastoma, IDH-wildtype and meningioma. Bologna, 21-23 September 2022.
- Biologia molecolare dei sarcomi dei tessuti molli. Corso “I sarcomi dei tessuti molli”. Torino, 24-26 May 2022.
- From hematoxylin & eosin to pixels: digital pathology and deep learning for colon cancer diagnosis. DeepHealth: Piedmont branch the clinical experience. Torino, 4 March 2022.
- Il ruolo del microambiente nelle metastasi cerebrali da tumore solido. – Mind your neighbours: interazioni microambiente-tumore. XXIV Congresso Nazionale e Corso Residenziale dell’Associazione Italiana di Neuro-Oncologia. Ancona, Italy, 29 November 2021.
- Slide seminar. La diagnosi anatomico-patologica delle malattie asbesto associate. Nodo cruciale nella risposta a quesiti medico-legali e nella ricerca multidisciplinare. Alessandria, 12-13 November 2021.
- Presentazione casi. Sfide diagnostiche nella patologia pediatrica e dell’adolescente. Webinar GIPPI, SIAPeC. 21 June 2021.

- Presentazione casi. Patologia ipofisaria: evoluzioni e rivoluzioni. Webinar GIPE-GINP, SIAPeC. 16 June 2021.
- Slide seminar di Neuropatologia. Meeting primaverile GINP con updates sulla nuova classificazione WHO dei tumori del SNC (5° ed.). Webinar GINP, SIAPeC. 13 May 2021.
- Aspetti mutazionali e divergenza molecolare nelle metastasi cerebrali. Diagnosi e terapia delle metastasi cerebrali: un paradigma di approccio multidisciplinare in Neuro-oncologia. Webinar AINO-SINch. 12 May 2021
- Funzione e composizione del Molecular Tumor Board. Diagnostica e trattamento nell'oncologia di precisione in Piemonte. Turin, Italy. 22 June 2020.
- La biologia molecolare dei sarcomi dei tessuti molli. I sarcomi dei tessuti molli. Turin, Italy. 25 February 2020.
- Sarcomi cutanei: inquadramento diagnostico. Terapie innovative in dermo-oncologia: non solo melanoma. Turin, Italy. 7-8 February 2020.
- Highlights sulle metastasi del SNC – Molecular divergence. XXIII Congresso Nazionale e Corso Residenziale dell'Associazione Italiana di Neuro-Oncologia. Udine, Italy, 10-12 November 2019.
- Biologia molecolare dei sarcomi dei tessuti molli. Stage sui sarcomi dei tessuti molli. Turin, Italy, 5-7 February 2019.
- Patologia metastatica cerebrale – Il ruolo della biopsia liquida oggi. Highlights in Neuro-oncologia. Turin, Italy, 28-29 September 2018.

#### Awards

- 2020-Today: Faculty member of the College of the European School of Oncology (ESO)
- Travel Grant for X EANO Meeting (European Association of NeuroOncology). Marseille, France (6-9 September 2012).
- Premio Optime 2012 – Award of Industrial Union of Turin for study merit.

#### Contributions to meetings and conferences

- About 90 abstracts submitted to meetings and conferences for oral or poster presentation (of which about 50 published on scientific journals).

#### Memberships and roles in scientific societies

- 2023 – 2026: Executive board of the Italian Association of Neuro-Oncology (AINO)
- 2023 – Today: European Organisation for Research and Treatment of Cancer (EORTC) – Active member – Brain Tumor Group (BTG)
- 2023 – Today: European Pituitary Pathology Group (EPPG)
- 2022 – Today: Member of the Italian Association of Neuro-Oncology (AINO)
- (AINO)
- 2021 – Today: Member of the European Association of Neuro-Oncology (EANO)
- 2018 – Today: Member of the Italian Association of Anatomic Pathology and Diagnostic Cytology (SIAPeC)
- 2021 – 2022: Member of the Association for Molecular Pathology (AMP)
- 2019 – 2021: Member of the European Society for Medical Oncology (ESMO)

#### Peer reviewing and editorial activity

- Peer reviewer of the following scientific journals (<https://publons.com/researcher/942331/luca-bertero/>):
  - Theranostics (IF 2018: 8.063)
  - Clinical and Translational Medicine (IF 2019: 7.919)
  - Cancers (IF 2018: 6.162)
  - Acta Neuropathologica Communications (IF 2018: 5.883)
  - Cellular Physiology and Biochemistry (IF 2017: 5.500)
  - Cellular Oncology (IF 2018: 5.020)
  - Laboratory Investigation (IF 2018: 3.684)
  - International Journal of Oncology (IF 2018: 3.571)
  - Journal of Neuropathology & Experimental Neurology (IF 2018: 3.460)
  - European Journal of Pharmacology (IF 2018: 3.170)
  - BMC Cancer (IF 2019: 3.150)

- Journal of Neuro-Oncology (IF 2018: 3.129)
- Expert Review of Molecular Diagnostics (IF 2018: 3.099)
- Oncology Reports (IF 2018: 3.041)
- International Journal of Molecular Medicine (IF 2018: 2.928)
- Virchows Archiv (IF 2018: 2.868)
- PLOS ONE (IF 2018: 2.776)
- Journal of Oncology (IF 2018: 2.600)
- Neurosurgical Review (IF 2018: 2.532)
- Journal of Clinical Pathology (IF 2019: 2.460)
- BioMed Research International (IF 2018: 2.197)
- Biochemistry and Cell Biology (IF 2018: 2.014)
- World Journal of Surgical Oncology (IF 2018: 1.966)
- Healthcare (IF 2019: 1.916)
- Oncology Letters (IF 2018: 1.871)
- International Journal of Biological Markers (IF 2018: 1.767)
- World Neurosurgery (IF 2018: 1.723)
- Tumori Journal (IF 2018: 1.234)
- BMJ Case Reports
- Respiratory Medicine Case Reports
- CNS Oncology
- Case Reports in Pathology
- Editorial activity:
  - 2022: Biomedicines – Guest Editor – Special issue: “Advanced Molecular Research on Ovarian Cancer”
  - 2022: Genes – Guest Editor – Special issue: “The Genomics of Glioblastoma”
  - 2020 – 2022: BioMed Research International – Academic Editor (IF 2019: 2.276)
  - 2020 – 2021: Biology – Topic Editor (Web of Science IF 2019: 3.796, Q1 Biology)
  - 2020: Biology – Guest Editor – Special issue: “Brain Metastases: Tackling a Frontier of Cancer Research and Treatment”

#### Grants/Participations to research projects

- 2023 – 2026: ERA-NET TRANSCAN 3 Joint Transnational Call for Proposals 2021 (JTC 2021) “Next generation cancer immunotherapy: Targeting the tumour microenvironment” – Project: RISEBrain – Reverting immune suppression to elicit brain metastasis control – Role: Principal investigator – University of Turin Partner Unit – Coordinating units: CNIO – Centro Nacional de Investigaciones Oncológicas, Madrid, Spain (Manuel Valiente) and Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany (Hind Medyouf) – Amount: 199.500€ (Total project funding: 1,380,760€).
- 2022: Cancersucks Foundation – Project: Observational study on NTRK fusions frequency in newly diagnosed IDH1/2 wild type gliomas with clinico-radiological and prognostic correlations. Role: Principal investigator – Amount: 15.000€.
- 2021: “Cassa di Risparmio di Torino” Foundation – Project: Uterine smooth muscle cell neoplasms: analysis of novel prognostic markers and therapeutic targets – File n° 2021.0553 – Role: Principal investigator – Amount: 25.000€.
- 2021: Piedmont and Valle d’Aosta Oncological Network – Project: Clinical, radiological, pathological and molecular evaluation of clinically significant, MRI-invisible prostate cancers. Role: Principal investigator – Amount: 30.000€.
- 2018-2022: Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR) – TESEO Project: “Traguardi di Eccellenza nelle Scienze mediche Esplorando le Omiche” under the programme “Dipartimenti di Eccellenza 2018 – 2022”, Project n° D15D18000410001.

- 2018: Piedmont and Valle d'Aosta Oncological Network – Project: Use of DNA methylation profiling for diagnosing CNS tumors, sarcomas and other rare tumors – Role: Principal investigator – Amount: 98.000€
- 2018 – 2022: EU Horizon 2020 Call: H2020-ICT-2018-2 Topic: ICT-11-2018-2019 – Project: “DeepHealth: Deep-Learning and HPC to Boost Biomedical Applications for Health”. – Role: Task leader (Work package 1 – Task 1.1: Use case definition and requirements) and key personnel of the UNITO unit – Coordinating unit: everis Spain SLU. – Total grant amount: 12.774.854,26€, Unit grant amount: 713.250€.
- 2017: Call AIFA – Project: “Identification and validation of new circulating biomarkers of GH-secreting pituitary tumors sensitivity to first generation somatostatin analogs treatment and improvement of acromegaly management.” – Role: Member of the University of Turin Research Unit – Coordinating unit: Divisione di Endocrinologia, Dipartimento di Patologia Umana dell’Adulto e dell’Età Evolutiva, Università di Messina, Italy.

Clinical studies participations

- Sub-Investigator of project CERN LAB07-0497 “Ependymoma tissue correlates of clinical course and response to therapy”. Principal investigator: Prof. Riccardo Soffietti.
- Sub-Investigator of clinical trial GO27819: “A randomized, double-blind, placebo-controlled, multicenter phase II study evaluating the efficacy and safety of onartuzumab in combination with bevacizumab or onartuzumab monotherapy in patients with recurrent glioblastoma”. Principal investigator: Prof. Riccardo Soffietti.
- Sub-Investigator of clinical trial CLDE225C2301: “A phase III, multi-center, open-label, randomized, controlled study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma”. Principal investigator: Prof. Riccardo Soffietti.
- Sub-Investigator of clinical trial CDX110-04: “An international, randomized, double-blind, controlled study of rindopepimut/GM-CSF with adjuvant temozolomide in patients with newly diagnosed, surgically resected, EGFRVIII-positive glioblastoma (The “ACT IV” Study)”. Principal investigator: Prof. Riccardo Soffietti.
- Sub-Investigator of clinical trial MO28347: “A double-blind, placebo-controlled, randomized, phase IIIb trial evaluating the efficacy and safety of standard of care (SOC) +/- continuous bevacizumab treatment following progression of disease (PD) in patients with glioblastoma (GBM) after first (1st)-line treatment with radiotherapy, temozolomide and bevacizumab). Principal investigator: Prof. Riccardo Soffietti.

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	Proficient	Proficient	Proficient	Proficient	Proficient
First Certificate in English (Grade A) – Levels B2					

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user  
[Common European Framework of Reference for Languages](#)

Digital skills

SELF-ASSESSMENT

Information processing	Communication	Content creation	Safety	Problem solving
Proficient	Proficient	Proficient	Proficient	Proficient

Levels: Basic user - Independent user - Proficient user  
[Digital competences - Self-assessment grid](#)

ECDL Core Full

- Proficient command of office suite (word processor, spread sheet, presentation software).

Driving licence A, B

I authorize treatment of my personal data included in this CV according to art. 13 of Law Decree n. 196 30-June-2003 ("Codice in materia di protezione dei dati personali") and to EU GDPR Regulation n° 2016/679.

Turin, 21 March 2023

